Often diagnosed in childhood or adolescence, Stargardt disease is an inherited form of macular degeneration causing central vision loss. The condition is sometimes referred to as juvenile or early onset macular degeneration.
What is Stargardt Disease?
Stargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss. Stargardt Disease is the most common form of inherited macular degeneration, affecting about 30,000 people in the U.S. The progressive vision loss associated with Stargardt disease is caused by the degeneration of photoreceptor cells in the central portion of the retina called the macula.
The retina is the delicate light-sensing tissue lining the inside wall of the back of the eye. Photoreceptor cells in the retina convert light into electrical signals, which are sent to the brain where they are processed to create the images we see. The macula, which is rich in cone photoreceptors, is responsible for sharp central vision — for tasks like reading, watching television, and looking at faces. Cones also provide vision in lighted settings and color perception.
Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. Some peripheral vision is usually preserved. Stargardt disease typically develops during childhood or adolescence, but the age of onset and rate of progression can vary. The retinal pigment epithelium (RPE), a layer of cells supporting photoreceptors, is also affected in people with Stargardt disease.
Symptoms
A loss or change in central vision is what usually leads to the initial diagnosis of Stargardt disease. A retinal doctor examining the retinas of a person with Stargardt disease will see characteristic yellowish flecks in the RPE. The flecks are deposits of lipofuscin, a byproduct of normal retinal cell activity. However, in Stargardt disease, lipofuscin accumulates abnormally.
The progression of vision loss in Stargardt disease is variable. Visual acuity (the ability to distinguish details and shape) may decrease slowly at first, accelerate, and then level off. Some peripheral vision is usually maintained.
Inheritance
Stargardt disease is usually an autosomal recessive condition caused by mutations in the gene ABCA4. It is inherited when both parents, called carriers, have one mutated copy of ABCA4 and a normal copy. Each child has a 25 percent chance of inheriting the two copies of ABCA4 (one from each parent) needed to cause the disease. Parents are unaffected carriers because they have only one mutated copy of ABCA4.
In a small percentage of cases, Stargardt disease is caused by mutations in the gene ELOVL4 and is passed on to children through the autosomal dominant inheritance pattern. In these cases, the parent has the disease and has a 50 percent chance of passing the mutated copy of ELOVL4 (and the disease) on to each child.
Living with the Disease
There are many services and accommodative and assistive resources available to people and families with Stargardt disease. Visit the Foundation’s Low Vision Resources page to learn about many of these resources. A low vision specialist can help recommend the resources that are right for you.
More information on managing Stargardt disease is in the Newly Diagnosed section of this website.
Genetic Testing
Genetic testing is available to help people definitively diagnose their condition and the risk of other family members or future offspring being affected. A genetic diagnosis can also help a person qualify for a clinical trial. Genetic counselors are excellent resources for discussing inheritability, family planning, genetic testing, and other related issues.
Research and Clinical Trials
For the latest research advances for Stargardt disease treatments, refer to the Foundation publication Stargardt Disease: Research Advances.
View a list of current clinical trials, many made possible by Foundation support
Stargardt disease page at www.ClinicalTrials.gov.
Next Section
Jump to Section
Latest News
-
Sep 17, 2024
Nanoscope Planning Phase 3 Clinical Trial of its Optogenetic Therapy for People with Advanced Stargardt Disease
The Phase 3 trial is expected to begin in Q1 2025
-
Sep 7, 2023
Foundation Funds 25 New Grants Totaling $15.1 Million in FY23
The global leader in retinal degenerative disease research supports a total of 93 research grants in its portfolio.
-
Nov 9, 2020
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
The Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
Sep 24, 2020
Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education (CME, COPE) Webinar
The event will review best practices for care and management of patients with inherited retinal diseases such as retinitis pigmentosa, Usher syndrome, and Stargardt disease.
-
Aug 21, 2020
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
New grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
Mar 31, 2020
COVID-19 Resources
The Foundation Fighting Blindness is closely monitoring the COVID-19 situation and its impact on the IRD community.
-
Feb 6, 2020
ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
-
Oct 2, 2019
Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness launch an open access program for patients with inherited retinal disease in the United States
The program will offer patients with inherited retinal disease no-cost genetic testing and genetic counseling in the United States. Look for updated information on how to participate to be posted in mid-October, with program registration starting shortly thereafter.
-
Aug 16, 2019
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
May 9, 2019
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Bipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
-
Jul 19, 2018
Foundation Fighting Blindness Urges Congress to Pass ‘Eye-Bonds’ Legislation
Bill Introduced in U.S. House Would Speed Up Cures for Blindness
-
Jun 15, 2018
Foundation Fighting Blindness Clinical Research Institute Hosted Workshop for ProgStar, the Largest Natural History Study for Stargardt Disease Ever Launched
The primary goal of the landmark study, funded by the Foundation, is to provide companies and researchers with disease-progression data and potential clinical trial endpoints to drive therapy development
-
Jun 8, 2018
Foundation Fighting Blindness and CheckedUp® Partner to Educate Retinal-Disease Patients About Research, Resources, and Emerging Therapies During Doctor Visits
The Foundation Fighting Blindness (the Foundation) and CheckedUp have formed a collaborative partnership to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases such as age-related macular degeneration, retinitis pigmentosa, and Stargardt disease during their visits to eye doctors.
-
Apr 4, 2011
Researchers Take another Critical Step toward Using Skin Cells to Treat Retinal Disease
A research team funded by the Foundation Fighting Blindness used an innovative repair technique to correct the disease-causing genetic defect in stem cells derived from a person’s skin — stem cells that hold the potential to treat their retinal degenerative condition.